• Emerging Growth Research raised its 12-month price target on Immuron to $4 from $3.9, maintaining a Buy-Extended rating.
• Report cited global product revenue of AUD 1.5 million in 3Q FY2026, up 16% year over year.
• Travelan sales drove growth in Australia, while U.S. revenue rose 1% in AUD terms due to foreign exchange effects.
• Analyst highlighted FDA clearance for Immuron to start Phase 2 trials of IMM-529 for C. difficile infections.
• Valuation case used a peer EV/revenue multiple of 6.22x, implying enterprise value near $33.3 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604220900ACCESSWRNAPR_____1159813) on April 22, 2026, and is solely responsible for the information contained therein.